On this powerful episode of Global Market Bulletin TV, host Leyla Gulen sits down with two of the key visionary minds behind Cryoport, Inc. (NASDAQ: CYRX)—Chief Scientific Officer Mark W. Sawicki, Ph.D. and Vice President of Corporate Development Thomas J. Heinzen. Together, they uncover the cutting-edge science, technology, and strategic execution that have positioned Cryoport as the world’s leading provider of advanced temperature-controlled supply chain solutions for the rapidly evolving life sciences sector.

In an era where precision, reliability, and biological integrity can determine the success of clinical trials, regenerative therapies, cell and gene therapies, and advanced biologics, Cryoport’s role has become more vital than ever. Dr. Sawicki and Mr. Heinzen highlight the company’s impressive 2022 performance, including a remarkable $237 million in total revenue, driven by a 27% surge in commercial income. They also reveal that Cryoport is now supporting 654 clinical trials across the globe—an unprecedented footprint that underscores the industry’s trust in Cryoport’s expertise and technology.

The executives dive deep into Cryoport’s operational excellence, explaining how their integrated systems ensure the safe delivery, stability, and viability of the world’s most sensitive biological materials. From cell therapies for cancer to breakthrough gene therapies for rare diseases, Cryoport’s logistics solutions sit at the heart of many of today’s most transformative medical advancements.

A major highlight of the interview is Cryoport’s newly announced strategic partnership with Syneos Health, a global biopharmaceutical solutions organization. This collaboration is designed to strengthen the clinical and commercial infrastructure supporting pharmaceutical innovators—offering a seamless synergy that accelerates timelines, enhances patient outcomes, and increases the reliability of global clinical development.

Dr. Sawicki brings unparalleled scientific insight to the conversation. With more than 15 years of expertise in drug discovery, pharmaceutical logistics, and immunology/oncology research, he breaks down the requirements, challenges, and scientific rigor behind building a successful cold-chain ecosystem. Meanwhile, Mr. Heinzen discusses the financing, strategic development, and market expansion efforts that have allowed Cryoport to scale its technology and services to meet skyrocketing industry demand.

For biotech investors, pharmaceutical executives, clinical research professionals, and anyone fascinated by the future of cell and gene therapy logistics, this interview is a rare opportunity to hear directly from the minds driving innovation in one of the most mission-critical sectors of global healthcare.

Stay ahead of industry-defining developments—Subscribe to Global Market Bulletin TV and turn on notifications to catch insightful CEO conversations, market intelligence, and exclusive executive features like this one.

CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.

About Cryoport Inc. (NASDAQ:CYRX)

Cryoport, Inc. is the global leader in temperature-controlled supply chain solutions for the life sciences sector, specializing in supporting cell and gene therapy, biopharmaceuticals, clinical research, animal health, and reproductive medicine. With unmatched technological innovation, Cryoport provides fully integrated, end-to-end cold chain logistics solutions that safeguard the integrity, viability, and stability of the most temperature-sensitive biological materials.

Cryoport’s portfolio includes industry-leading technologies such as:

• Cryoport Express® — a state-of-the-art liquid nitrogen dry vapor shipping system designed for ultra-cold transport
• C3™ 2–8°C controlled temperature solution — engineered for biological materials requiring precision temperature environments
• SmartPak II® — Cryoport’s advanced condition monitoring system offering real-time visibility of temperature, location, and shipment integrity
• Cryoportal® — the company’s proprietary logistics management platform that integrates data, operational workflow, geo-sensing technology, and 24/7 client support to deliver a seamless supply chain experience

With more than 650 global clinical trials relying on its systems and 10 commercial therapies currently supported, Cryoport has become an indispensable partner to biotechnology and pharmaceutical companies advancing next-generation therapies. The company continues to expand its global footprint through strategic partnerships, acquisitions, and state-of-the-art logistics centers designed to meet the needs of the world’s most complex therapeutic modalities.

READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.